Promoter holding
64.27%
IL
Intron Life Sciences Private Limited - Due diligence report
A 360° intelligence report on Intronlifesciences: trust score, financial health, credit view, compliance, directors, growth and distress sig…
Full Due-Diligence Report + Documents
- Unlock all financial figures & 5-year trends
- Full trust, health & credit-risk scores
- Director details, charges & MCA documents
₹700
₹449
Save ₹251
excl. GST
Or from ₹279/report with credits
View credit packages
Company Credits – Starter
- One credit unlocks this full due-diligence report
- Use across any company’s report, anytime
- Credits valid for 12 months
Choose your own credit amount
View credit packages
Intronlifesciences — 360° Intelligence Report
Generated from MCA filings & public records91/100
Trust Score
Low Risk
Intronlifesciences is assessed as Low Risk with a Trust Score of 91/100. Intronlifesciences is an active private limited indian non-government company incorporated in 2018, operating in the Life Sciences sector. The company has shown revenue growth across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a low compliance risk and low financial risk profile.
Report generated on 12 Aug 2026 from the latest processed filings. Intron Life Sciences Private Limited snapshot & full profile →
Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.
02
Score Card
Higher is safer · rule-based & explainableTrust ScoreLow Risk
91/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreLow Risk
93/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreLow Risk
95/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreLow Risk
95/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
85/100
Board strength, DIN status, churn and network.
Growth ScoreLow Risk
95/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
90/100
Early-warning signals - higher means fewer warnings.
03
Financial Intelligence Dashboard
Consolidated · 5 filed year(s)Unlock the full 5-year financial dashboard with charts and year-wise figures.
Get full accessScores and observations on this page are already computed from the real filings - only the underlying figures are locked.
04
Credit & Compliance Intelligence
Why the scores are what they are
Credit Risk Score: 95/100 Low Risk
- Liabilities ≈ 38% EBITDA - serviceable.
- Moderate gearing (D/E 1.42).
- Working-capital cover adequate.
- Profitable - internal accruals available.
- Externally credit-rated (B).
Charges position: 5 open (24.00 cr) · 2 satisfied (22.00 cr).
Banking relationships (from registered charges)
| Lender | Charges | Amount |
|---|---|---|
| Axis Bank Limited | 1 | 48.0 cr |
| Others | 1 | 48.0 cr |
| Hdfc Bank Limited | 5 | 48.0 cr |
Compliance Score: 93/100 Low Risk
- Company status is Active as per MCA.
- Annual filings current (balance sheet Mar 2025).
- Litigation present in 1 court forum(s).
- 7 active GST registration(s).
Legal cases on record (1)
05
Director Intelligence
Stability score: 85/100| Name | DIN / PAN | Designation | Appointed | Tenure | DIN status |
|---|---|---|---|---|---|
| SARANYA MUKUL AGRAWAL | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| RONAK MODI | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| SREEMANNARAYANA MURALI KRISHNA PASUMARTHI | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| PAVAN KUMAR VELPURI | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| VIJAY RAMVALLABH KHETAN | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| MANISH GUPTA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
- 6 directors on the board.
- No disqualified or deactivated DINs.
- 2 director exit(s) in the last 3 years.
Director & KMP remuneration (FY 2023)
| Name | Designation | Total remuneration |
|---|---|---|
| A K Sharma | Managing Director | 2.4 cr |
| R Mehta | Whole-time Director | 1.6 cr |
| S Iyer | CFO | 95.0 L |
Remuneration is disclosed in the latest annual return. Unlock full report
06
Ownership & Group Intelligence
As per FY 2023 annual returnPublic / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
India Life Sciences Fund Iii, Llc
Subsidiaries
1
Group entities
1
Capital events
1 allotment(s) · 7 transfer(s)
Promoters hold a dominant controlling stake - exact percentages are part of the full report.
| Group entity | Relationship | % held |
|---|---|---|
| Intron Holdings Asia Pte Limited | Subsidiary Company | 74.00% |
| Intron Life Sciences Vietnam Company Ltd | Subsidiary Company | 74.00% |
| Biome Biologicals Private Limited | Subsidiary Company | 74.00% |
| Pt Intron Life Sciences Indonesia | Subsidiary Company | 74.00% |
| India Life Sciences Fund Iii, Llc | Holding Company | 74.00% |
| Intron Llife Sciences Thailand Company Limited | Associate Company | 74.00% |
Key managerial personnel: SREEMANNARAYANA MURALI KRISHNA PASUMARTHI (Managing Director) · PAVAN KUMAR VELPURI (Whole-time director)
Full shareholding pattern, group structure & capital events →
07
Risk Intelligence Center
Growth 95 · Distress 90
Growth signals & trust indicators
Revenue acceleration: +2.1x over 4 year(s).
Latest year revenue grew 24%.
Profit expanded 0.86 year-on-year.
Asset base grew 61% - capacity expansion.
Net margin improved to 38%.
EPFO headcount growing - hiring signal.
Operating for 7 years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
5 open charge(s) registered - assets are encumbered.
1 court case(s) on record - see the legal section for details.
08
Stakeholder Verdicts
Vendor · Banker · InvestorVendor due diligence92/100
Favourable indicators
Suitability as a supplier / customer counterparty.
- Statutory record is clean.
- No distress signals on file.
- Financial filings available for verification.
Banker assessment94/100
Favourable lending indicators
Indicative lending comfort for banks, NBFCs and trade credit.
- Debt capacity assessed from filed statements.
- 5 open charge(s) of 24.00 cr already registered.
- Compliance record supports lending.
Investor view94/100
Positive growth indicators
Growth quality and scalability through an investor lens.
- 6 growth signal(s) detected.
- Margin and return trends computable from filings.
- Management team looks stable.
09
MCA Filings & Events Timeline
Latest 15 events08 Oct 2025
Director appointed
SARANYA MUKUL AGRAWAL (Nominee Director)
Director appointed
VIJAY RAMVALLABH KHETAN (Nominee Director)
Director appointed
MANISH GUPTA (Nominee Director)
Director ceased
NITHYAGOVIND
30 Sep 2025
Last AGM held
Annual general meeting
31 Mar 2025
Latest balance sheet
Filed with ROC
11 Nov 2024
Charge created
Hdfc Bank Limited - 20.23 Lakh
26 Feb 2024
Director ceased
PAVAN KUMAR VELPURI
15 Nov 2023
Charge created
Hdfc Bank Limited - 20.85 Lakh
01 Mar 2023
Charge satisfied
Others
09 Feb 2023
Charge created
Hdfc Bank Limited - 61.00 Lakh
13 Jan 2023
Charge created
Axis Bank Limited - 22.30 cr
02 Nov 2022
Director appointed
RONAK MODI (Company Secretary)
24 May 2022
Charge satisfied
Hdfc Bank Limited
25 Apr 2022
Charge created
Hdfc Bank Limited - 68.30 Lakh
10
Key Observations
Auto-generated from the data aboveRevenue grew 1.42 over the last 4 financial year(s).
Net profit margin moved from 2.1x to 24%.
Debt-to-equity stands at 0.86 - manageable leverage.
Net worth is positive.
Compliance record is strong - status, filings and flags are clean.
6 active director(s) / partner(s); board looks stable and experienced.
7 active GST registration(s) indicate ongoing business operations.
Operates a group structure with 1 subsidiary(ies) - assess on a consolidated basis.
Carries an external credit rating of B from Care.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a dominant controlling stake as per the FY 2023 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 1 security allotment(s) - amounts available in the full report.
| Company | CIN | Location |
|---|---|---|
| Jfl Life Sciences Limited | L24230GJ2010PLC060417 | Ahmedabad, Gujarat, India |
| Sunil Healthcare | L24302DL1973PLC189662 | New Delhi, Delhi, India |
| Neochem Bio Solutions Limited | L24304GJ2017PLC097754 | Daskroi, Gujarat, India |
| Reno Mercantile Private Limited | U28100TN2009PTC073172 | Chennai, Tamil Nadu, India |
| Pandian Chemicals Limited | U24297TN1972PLC006245 | Madurai Dt, Tamil Nadu, India |
| Sesa | U24247DL2018PTC452131 | New Delhi, Delhi, India |
| Konkem Industries Private Limited | U24304GJ2017PTC097514 | Ahmedabad, Gujarat, India |
| Cosmas Research Lab Limited | U24110PB2008PLC031925 | Ludhiana, Punjab, India |
12
Who Uses This Report
CA · CS · Banker · Investor · VendorChartered Accountants (CA)
Verify Intronlifesciences before audits and certifications: compliance score 93/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.
Company Secretaries (CS)
Track statutory health of Intronlifesciences: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.
Bankers & NBFCs
Current banker verdict: Favourable lending indicators. Credit risk score 95/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.
Investors & Analysts
Investor view: Positive growth indicators. Growth score 95/100, margin trends, ownership structure and peer set for Intronlifesciences - screening before a deeper diligence.
Vendors & Procurement Teams
Vendor verdict: Favourable indicators. Trust score 91/100, distress signals and MSME payment-delay disclosures - know whether Intronlifesciences pays its suppliers before you extend credit terms.
Lawyers & Compliance Teams
Litigation footprint (1 case(s) on record), regulatory flags, charge documents trail and director networks for Intronlifesciences - groundwork for KYC, onboarding and disputes.
13
Frequently Asked Questions
Is Intronlifesciences an active company?
Intronlifesciences has MCA status “Active” with a compliance score of 93/100 (Low Risk).
Is Intronlifesciences financially healthy?
Intronlifesciences has a Financial Health Score of 95/100 (Low Risk) based on its filed financial statements.
Should I do business with Intronlifesciences?
Its overall Trust Score is 91/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.
Who controls Intronlifesciences?
The ultimate holding entity is India Life Sciences Fund Iii, Llc. 6 active director(s) are on record.
Does Intronlifesciences have loans or charges against its assets?
5 open charge(s) are registered against its assets, and 2 earlier charge(s) stand satisfied.
Is Intronlifesciences up to date with its ROC filings?
Annual filings current (balance sheet Mar 2025). Overall compliance score: 93/100 (Low Risk).
Is it risky to lend to Intronlifesciences?
Its Credit Risk Score is 95/100 (Low Risk). Banker verdict: Favourable lending indicators.
Disclaimer: This report is generated automatically from MCA filings and public records as available
in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the
underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are
not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice.
Verify from official sources and consult a qualified professional before any business, lending or investment decision.
If you represent this company and believe any information is inaccurate or outdated,
report it here and we will review promptly.
